Zenshine Pharmaceuticals

Company snapshot

Zenshine is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key bi

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zenshine Pharmaceuticals. Not investment advice.

• What is Zenshine Pharmaceuticals?

  Nanjing Zenshine Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Unresectable Hepatocellular Carcinoma (HCC), Unexplained Recurrent Miscarriage and Recurrent Implantation Failure, Breast Feeding, Gastric Cancers, Prostate Canc

• Is Zenshine Pharmaceuticals publicly traded?

  Zenshine Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Zenshine Pharmaceuticals develop or market?

  We link 17 drug profile(s) where Zenshine Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shine-europe-b-v#company-drugs.

• What are the latest developments for Zenshine Pharmaceuticals?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zenshine Pharmaceuticals focus on?

  Zenshine Pharmaceuticals focuses on Unresectable Hepatocellular Carcinoma (HCC), Unexplained Recurrent Miscarriage and Recurrent Implantation Failure, Breast Feeding based on our analysis of their pipeline programs and drug development activities.